I confess, I really enjoy it when somewhat grandiose programs that are supposed to transform health care pretty much fall far short of the projected effects. So it is with pay-for-performance. An article in Health Affairs looks at the Medicare hospital pay-for-performance initiatives and expresses concerns about their operation and effects. (HA Article) Three primary programs include the Hospital-acquired Conditions Reduction program, under which hospitals must avoid patients contracting certain infections or other conditions or get a payment reduction; the Value-Based Purchasing program, which also adjusts payment in part based on quality measures; and the Hospital Readmissions Reduction initiative, which we have frequently discussed. By 2017 hospitals could lose as much as 6% of base payments from Medicare under these three programs. As you might expect there can be overlap in the quality measures in the three programs. The value-based purchasing program is budget-neutral but in 2015 almost 45% of hospitals lost some reimbursement, generally small amounts. The readmission program is not budget-neutral and is ensnaring increasing numbers of hospitals, which in total lost over $420 million in Medicare reimbursements for 2015. Many of the penalized hospitals under this program and the hospital-acquired conditions program were major institutions with otherwise good markers of quality of care. As the article recites, many health care experts have criticized the design of the measures used in these programs, the failure to have adequate case-mix adjustment, the inconsistency in data collection and reporting that makes consistency of results unlikely and the administrative burden and costs imposed upon the hospitals. It is also very difficult to attribute any improvement in quality on these programs as opposed to other factors. All these issues have been presented to CMS, which generally seems to just ignore them.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Cano Health apparently cannot, as it declares bankruptcy due to too much debt. Building primary care centers to serve Medicare, Medicaid and commercial populations, which is Cano’s business, was hot...
February 6, 2024
Turquoise health raises a fresh $30 million in capital for its price transparency platform, as the market for funding health care companies isn’t quite dead yet.
January 24, 2024
I am co-f0under of a company that manages cell and gene therapy for health plans. Cell therapy has made a big difference for many cancer patients but like all new...
January 24, 2024
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace